TP53 and carcinoma: However, TCG>TTG substitutions (also substantially enriched in POLEmut carcinomas 32) accounted for 6/24 (25%) of the TP53 variants in POLEmut–p53abn in contrast to single‐classifier p53abn ECs in which these alterations did not occur (p ≤ 0.001).